Endocrine and Metabolic Science最新文献

{"title":"The association between testosterone levels and diabetic nephropathy in Egyptian men with type 1 Diabetes Mellitus","authors":"Mina Michael Nesim,&nbsp;Maram Mohamed Maher Mahdy,&nbsp;Laila Mahmoud Ali Hendawy,&nbsp;Hadeer Osama Abd Eltawab Mohamed,&nbsp;Amr Mahmoud Mohamed Abd El Hady Saleh","doi":"10.1016/j.endmts.2025.100233","DOIUrl":"10.1016/j.endmts.2025.100233","url":null,"abstract":"<div><h3>Background</h3><div>Type 1 diabetes mellitus is a chronic illness characterized by the body's inability to produce insulin due to the autoimmune destruction of beta cells in the pancreas. It can develop in adults and is often onset in childhood.</div></div><div><h3>Objectives</h3><div>To assess testosterone levels in Egyptian men with type 1 diabetes mellitus with and without nephropathy and identify its correlation with microalbuminuria.</div></div><div><h3>Subjects and methods</h3><div>This study was a case control study conducted at Diabetes outpatient clinic at Ain Shams University Hospital. The study was performed on diabetic subjects aging above 20 years old. The study included 120 participants with diabetes divided into 3 groups: 40 cases with type 1 diabetes and diabetic nephropathy, 40 cases with type 1 diabetes without diabetic nephropathy, 40 healthy males as a control group.</div></div><div><h3>Result</h3><div>Testosterone levels were higher in patients with T1DM than in healthy controls. Total testosterone levels were significantly higher in T1DM patients with diabetic nephropathy compared to those without diabetic nephropathy, mean = (653.208 ± 128.810) ng/dl versus (572.104 ± 146.024) ng/dl, p-value&lt;0.01. Sex hormone-binding globulin showed no association with T1DM or diabetic nephropathy, p-value = 0.l.</div></div><div><h3>Conclusion</h3><div>The current study showed that testosterone levels were higher in participants with T1DM than in healthy controls. Also we found that total testosterone levels were significantly higher in T1DM participants with diabetic nephropathy compared to those without diabetic nephropathy. These results implicate that elevated testosterone levels could be the underlying cause of nephropathy in T1DM patients with nephropathy, and indicate that they may have a degree of androgen resistance for further research.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100233"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical profile of hypertension patients in primary health Care in Cirebon Regency, Indonesia","authors":"Tiar Masykuroh Pratamawati ,&nbsp;Ahmad Fariz Malvi Zamzam Zein ,&nbsp;Uswatun Khasanah ,&nbsp;Donny Nauphar ,&nbsp;Vincentius S.W. Budhyanto ,&nbsp;Idrus Alwi ,&nbsp;Asmarinah","doi":"10.1016/j.endmts.2025.100232","DOIUrl":"10.1016/j.endmts.2025.100232","url":null,"abstract":"<div><h3>Introduction</h3><div>Hypertension is a catastrophic non-communicable disease increasing in prevalence globally. This study aimed to assess the clinical profile of hypertensive patients in primary health care services in Cirebon Regency, Indonesia.</div></div><div><h3>Method</h3><div>This descriptive study employed a purposive sampling method, recruiting 97 adult patients diagnosed with essential hypertension at the Talun Community Health Center, Cirebon Regency, West Java, from November 2023 to February 2024. Patients with secondary hypertension or hypertension in pregnancy were excluded. Data were collected through questionnaires, blood pressure measurements, and analysis of blood and urine samples. The clinical profile included family history, control status of hypertension, lifestyle factors, cardiometabolic parameters, and mental health status. Lifestyle factors encompassed both dietary habits and physical activity levels. Cardiometabolic parameters included body mass index (BMI), HbA1c, lipid profile, kidney function, and electrocardiogram. Mental health status was measured using the Depression Anxiety Stress Scales (DAAS). Univariate analysis was stated in frequencies, mean, or median.</div></div><div><h3>Results</h3><div>The mean age of the participants was 51.33 (±1.07) years, predominantly female (84.54 %). Subjects with a family history of hypertension were 52.58 %, and 75.3 % had uncontrolled blood pressure. Most subjects (79.17 %) engaged in light daily physical activity, while only 4.2 % reported excessive sodium intake. The average BMI was 26.04 kg/m², with 35.5 % classified as class 1 obese. Additionally, 12.4 % of subjects had diabetes mellitus, 41.2 % were prediabetic, and 80.41 % had dyslipidemia. Albuminuria was detected in 54.6 % of participants, and 7.2 % showed evidence of left ventricular hypertrophy. Regarding mental health, 37.50 % experienced anxiety, 8.33 % reported stress, and 4.17 % suffered from depression.</div></div><div><h3>Conclusion</h3><div>The findings indicate a significant proportion of hypertensive patients in primary health care in Cirebon Regency have uncontrolled blood pressure. Sedentary lifestyle, obesity, dyslipidemia, albuminuria, and prediabetes were prevalent among these patients. Moreover, anxiety affected more than a third of the studied subjects, highlighting the need for comprehensive management strategies for managing hypertensive patients.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of adipose tissue-derived hormones asprosin and leptin in the onset of depressive symptoms in newly diagnosed prediabetic individuals","authors":"Faize Elif Bahadir ,&nbsp;Ozlem Unay Demirel ,&nbsp;Melike Yavuz ,&nbsp;Ozum Firat ,&nbsp;Irem Yogurtcu ,&nbsp;Yavuz Govdeli ,&nbsp;Yavuz Furuncuoglu","doi":"10.1016/j.endmts.2025.100231","DOIUrl":"10.1016/j.endmts.2025.100231","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes and depression are common chronic conditions that often co-occur, likely driven by complex mechanisms that are not yet fully understood. Chronic low-grade inflammation may serve as a shared underlying factor in both conditions. This study aimed to determine whether adipose tissue-derived hormones asprosin and leptin, particularly asprosin, which is associated with inflammatory cytokines in glucose metabolism dysregulation and has not been studied in this context—might influence the onset of depressive symptoms.</div></div><div><h3>Methods</h3><div>112 participants were recruited from drug-naïve individuals. Blood samples were collected, anthropometric data recorded, the Beck Depression/Anxiety Inventories administered. Adapted questions assessed physical and social activity, as well as sleep habits, to account for environmental factors. After applying the exclusion criteria, participants were divided into prediabetic (n = 32) and normoglycemic groups (n = 30).</div></div><div><h3>Results</h3><div>In the prediabetic group CRP was elevated (p &lt; 0.001), with a positive correlation between asprosin and leptin (p &lt; 0.001). Asprosin was positively correlated with TNF-α (p = 0.004), IL-6 (p = 0.002), and ESR (p &lt; 0.001), and leptin with TNF-α (p = 0.008) and ESR (p = 0.018) but not with depressive symptoms or anxiety. Depressive symptoms were higher in prediabetic individuals with poor sleep quality.</div></div><div><h3>Conclusion</h3><div>In groups with similar social and physical activity levels, poor sleep quality was associated with increased depressive symptoms. While asprosin and leptin correlated with higher inflammatory cytokines, they showed no significant association with depression, possibly due to the small sample size and early-stage evaluation. Larger studies are needed to confirm any potential link between these hormones and depression.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus","authors":"To Anh Tan Le ,&nbsp;An Viet Tran ,&nbsp;Son Kim Tran ,&nbsp;Chau Minh Tran ,&nbsp;Dang Khoa Dang Tran ,&nbsp;Duy Huu Duong ,&nbsp;Toan Hoang Ngo","doi":"10.1016/j.endmts.2025.100230","DOIUrl":"10.1016/j.endmts.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.</div></div><div><h3>Objectives</h3><div>This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.</div></div><div><h3>Results</h3><div>In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p &lt; 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.</div></div><div><h3>Conclusion</h3><div>The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment","authors":"Arghavan Ghafari ,&nbsp;Malihe Maftoohi ,&nbsp;Mohammadamin Eslami Samarin ,&nbsp;Sepideh Barani ,&nbsp;Majid Banimohammad ,&nbsp;Reza Samie","doi":"10.1016/j.endmts.2025.100228","DOIUrl":"10.1016/j.endmts.2025.100228","url":null,"abstract":"<div><div>Polycystic Ovary Syndrome (PCOS) is a prevalent reproductive disease influencing 4–20 % of women, often resulting in delayed diagnosis and correlated metabolic issues such as obesity and insulin resistance, impacting their quality of life. Diagnosis is guided according to the Rotterdam criteria, oligo-anovulation, polycystic ovary morphology, and incorporating hyperandrogenism, with Anti-Müllerian hormone as an indicator for ovary morphology. PCOS management necessitates a multifaceted approach, including lifestyle modifications, weight loss strategies, dietary adjustments, and pharmacological interventions. Lifestyle interventions, comprising exercise regimens, dietary modifications, and behavioral strategies, exhibit the potential to enhance metabolic health among PCOS patients. While no singular diet or exercise regimen emerges as superior, the Mediterranean and ketogenic diets have demonstrated favorable effects. Pharmacological interventions, such as combined oral contraceptives, metformin, and clomiphene citrate, assume pivotal roles in regulating menstrual cycles and mitigating hyperandrogenism symptoms. Personalized approaches, tailored to individual responses, are imperative for optimizing outcomes in the management of PCOS.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of metabolic syndrome in the occurrence of hearing disorders in the Democratic Republic of Congo","authors":"Jérôme Gedikondele Sokolo ,&nbsp;Aliocha Natuhoyila Nkodila ,&nbsp;Gabriel Mabwaka Lema ,&nbsp;Richard Nzanza Matanda ,&nbsp;Pius Zakayi Kabututu ,&nbsp;Benjamin Longo-Mbenza","doi":"10.1016/j.endmts.2025.100227","DOIUrl":"10.1016/j.endmts.2025.100227","url":null,"abstract":"<div><h3>Background</h3><div>The assessment of hearing function in human life is important, because good hearing is important for social participation and inclusion in employment and education. The objective of this study is to evaluate the influence of metabolic syndrome in the occurrence of hearing disorders in patients followed in hospitals in Kinshasa.</div></div><div><h3>Methods</h3><div>This was an analytical cross-sectional study that included 400 patients consulted in 7 hospitals in the city province of Kinshasa during the period from January 2005 to September 2020. Sociodemographic, clinical, and biological data were analyzed. Multivariate logistic regression analysis and discriminant analysis were used as a basis to document the factors associated with hearing disorders in the study population; and the statistical significance threshold was <em>p</em> &lt; 5 %.</div></div><div><h3>Results</h3><div>The frequency of hearing loss was 40.1 % in patients with metabolic syndrome. Risk factors identified for the occurrence of hearing loss in patients with metabolic syndrome were age ≥ 60 years (aOR: 2.73 95 % CI: 1.37–5.42), waist circumference &gt; 85 cm (Female) or &gt; 94 cm (Male) (aOR: 2.65 95 % CI: 1.37–3.72); blood glucose ≥126 mg/dL (aOR: 2.86 95 % CI: 1.32–6.17), BMI ≥25 kg/m2 (aOR: 2.73 95 % CI: 1.89–3.32) and in patients with insulinemia &gt;10 IU/L (aOR: 3.37 95 % CI: 1.47–7.76).</div></div><div><h3>Conclusion</h3><div>The frequency of hearing loss is high in the population studied. The components of the metabolic syndrome were identified as independent determinants of hearing loss.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100227"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distribution of norepinephrine and acetylcholine receptors in ovarian structures across reproductive and senescent phases in rats","authors":"Juan Bravo-Benítez ,&nbsp;María E. Rivera-Castro ,&nbsp;Cesar F. Pastelín ,&nbsp;Ithayetsi Sarmiento ,&nbsp;Amayrani Hernández ,&nbsp;Alfonso Díaz ,&nbsp;Carolina Morán","doi":"10.1016/j.endmts.2025.100225","DOIUrl":"10.1016/j.endmts.2025.100225","url":null,"abstract":"<div><div>The autonomic nerves in the mammalian ovary are responsible for transmitting the neurotransmitters norepinephrine and acetylcholine, among others. Interestingly, some ovarian innervation becomes more active toward the end of life. The objective of this study was to examine the presence of adrenergic (A1R) and muscarinic (M1R) receptors in adult and senescent female rats. Female rats were divided into three groups according to age: young adults aged 3 to 5 months (3M), middle-aged rats aged 12 months (12M), and senescent rats aged 15 months (15M). Primary antibodies targeting the α1-adrenergic receptor, μ1-muscarinic receptor, 17β-estradiol receptor (ER), and α1-progesterone receptor (PR) were used. Immunoreactivity analysis covered the ovarian stroma and cells around functional structures such as the corpus luteum, ovarian cysts, and follicles. Both receptor antibodies stained these structures, but the noradrenergic binding was three times more abundant than cholinergic binding. The number of immunoreactive cells expressing the A1R/ER combination was significantly increased in 12M rats, principally around follicles or cysts. M1R/PR staining was similarly increased in the 12M group, but the principal signal source was the stroma cells. The autonomic nervous system appears to participate in the loss of function of these structures with age in the rat ovary.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monosodium glutamate (MSG) exposure induced oxidative stress and disrupted testicular hormonal regulation, exacerbating reproductive dysfunction in male WISTAR rats","authors":"Adesua Emmanuel Ogunmokunwa,&nbsp;Babatunde Oluwaseun Ibitoye","doi":"10.1016/j.endmts.2025.100226","DOIUrl":"10.1016/j.endmts.2025.100226","url":null,"abstract":"<div><h3>Background</h3><div>Monosodium glutamate (MSG) is a common food additive linked to various health concerns, including potential reproductive toxicity.</div></div><div><h3>Objective</h3><div>To investigate the effects of chronic, low-dose MSG on testicular hormones and oxidative stress biomarkers in adult male Wistar rats.</div></div><div><h3>Methods</h3><div>Thirty male Wistar rats were divided into five groups (<em>n</em> = 6 per group). The control group received distilled water, while the experimental groups were orally administered MSG at 30, 100, 300, and 1000 mg/kg body weight for 65 days. Hormonal levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were measured using ELISA. Testicular oxidative stress markers, including malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), were assessed.</div></div><div><h3>Results</h3><div>MSG caused a dose-dependent decrease in LH, FSH, and testosterone levels, with the highest dose (1000 mg/kg) exhibiting the most significant reductions. MDA levels increased proportionally with MSG dosage, indicating heightened oxidative stress. Conversely, the activities of antioxidant enzymes (SOD, CAT, GSH, GPx) were significantly diminished, reflecting impaired antioxidant defences.</div></div><div><h3>Conclusion</h3><div>Chronic MSG exposure disrupts hormonal regulation and induces oxidative stress in a dose-dependent manner, potentially impairing male reproductive health. These findings underscore the need for further studies on the long-term reproductive effects of MSG and possible protective interventions.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100226"},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acromegaly: Is earlier diagnosis possible? Exploration of a screening algorithm to select high-risk patients","authors":"Tessa N.A. Slagboom ,&nbsp;David de Jong ,&nbsp;Peter H. Bisschop ,&nbsp;Madeleine L. Drent","doi":"10.1016/j.endmts.2025.100223","DOIUrl":"10.1016/j.endmts.2025.100223","url":null,"abstract":"<div><h3>Purpose</h3><div>Given the ongoing need to reduce the delay in diagnosis of acromegaly, the aim of the current study was to develop a screening algorithm that: finds as many patients as possible who have already been diagnosed with acromegaly (=sensitivity), while identifying a limited number of additional patients who are at risk for acromegaly as a proxy for specificity.</div></div><div><h3>Methods</h3><div>CTcue data mining software (version 4.7, IQVIA Inc., USA) was used to develop a screening algorithm. Data were extracted from the electronic health records of a tertiary centre. Multiple sources (literature review, real-world evidence and expert opinion) were used to identify predictors such as clinical manifestations, comorbidities and frequently consulted specialists, for inclusion in the algorithm. Based on different combinations of predictors, several exploratory search strategies were constructed in CTcue and algorithms with the highest sensitivity were further adapted.</div></div><div><h3>Results</h3><div>A total of 68 predictors were identified and grouped into 5 categories. After exploratory analysis and fine-tuning, an algorithm combining pathognomonic changes in clinical appearance with manifestations considered by medical experts to be most characteristic of acromegaly (hyperhidrosis, sleep apnoea, arthralgia, headache and type 2 diabetes mellitus) detected 48/90 of patients with previously diagnosed acromegaly, while identifying an additional 1844/1,7 million of possible at-risk patients.</div></div><div><h3>Conclusion</h3><div>We found that our best algorithm led to the detection of more than half of patients with previously diagnosed acromegaly. The same algorithm identified 0.1 % of the hospital population as potentially having acromegaly, which is approximately 10 times higher than the estimated worldwide prevalence. These results seem promising but need further improvement and validation.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100223"},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective clinical analysis of time to recovery from diabetic ketoacidosis in Ethiopia","authors":"Angefa Ayele ,&nbsp;Dube Jara ,&nbsp;Alo Edin ,&nbsp;Digafe Hailu ,&nbsp;Mihiret Kifle ,&nbsp;Yohannes Fekadu","doi":"10.1016/j.endmts.2025.100224","DOIUrl":"10.1016/j.endmts.2025.100224","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes is a metabolic disorder that affected &gt; or = 500 million people in 2021. Diabetic ketoacidosis is the most serious acute complication. Because of the significant health burden of diabetic ketoacidosis, we performed a retrospective study on the recovery time and predictors among adult diabetic mellitus patients in selected public hospitals in Southern Oromia in Ethiopia.</div></div><div><h3>Methods</h3><div>A retrospective follow-up study was conducted of 316 randomly selected adult diabetic ketoacidosis patients admitted between January 1, 2020, and July 31, 2023. A structured checklist was utilized. Data were entered into Epi-data version 4.6 and analyzed with STATA version 17, employing Kaplan-Meier survival curves, log-rank tests, and Cox-proportional hazards models to identify predictors. Results from bivariable and multivariable Cox-regression were reported via adjusted hazard ratio with 95 % confidence intervals.</div></div><div><h3>Results</h3><div>This study included 316 participants, with 256 adults (81.01 %) recovering throughout the follow-up period. The overall DKA recovery rate was 23.8 per 1000 person-hours (95 % CI: 22.21–27.07), and the median recovery time was 42 hr. Significant predictors of recovery time included random blood glucose level [AHR (95 % CI): 0.58 (0.38–0.90)], duration of diabetes mellitus [AHR (95 % CI): 0.24 (0.14–0.69)], and severity of DKA [AHR (95 % CI): 0.46 (0.16–0.84)].</div></div><div><h3>Conclusion</h3><div>The median DKA recovery time was prolonged, increasing the risk of complications. Blood glucose level, diabetes duration, and DKA severity were predictors of recovery time. Therefore, targeting these factors through research and interventions may improve outcomes and reduce DKA recovery duration.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143349976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}